VXRT Vaxart Inc.
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.
Company profile
Ticker
VXRT
Exchange
Website
CEO
Andrei Floroiu
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Amgen • Gilead Sciences • Biogen • QIAGEN • Moderna • BioNTech SE • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics • Innate Pharma ...
Former names
Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., Nabi Biopharmaceuticals, Nabi, Nabi Biopharmaceuticals, North American Biologicals Inc
SEC CIK
Corporate docs
IRS number
591212264
VXRT stock data
()
Calendar
6 Aug 20
8 Aug 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|
| Revenue | 523K | 2.9M | 3.92M | 454K | |
| Net income | -8.98M | -1.3M | -6.41M | -5.26M | |
| Diluted EPS | -0.12 | -0.02 | -0.13 | -0.32 | |
| Net profit margin | -1716% | -44.69% | -164% | -1159% | |
| Operating income | -8.53M | -694K | -5.63M | -4.71M | |
| Net change in cash | 14.53M | 16.35M | -6.03M | 3.3M | |
| Cash on hand | 44.39M | 29.86M | 13.51M | 19.54M | |
| Cost of revenue |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 11 | |
|---|---|---|---|---|---|
| Revenue | 9.86M | 4.16M | 5.84M | 14.84M | |
| Net income | -18.65M | -18.01M | -9.58M | -4.53M | |
| Diluted EPS | -0.86 | -2.9 | -91.65 | ||
| Net profit margin | -189% | -433% | -164% | -30.54% | |
| Operating income | -15.79M | -21.76M | -10.02M | -9.76M | |
| Net change in cash | 2.07M | 9.87M | -55.95M | 3.96M | |
| Cash on hand | 13.51M | 11.44M | 1.57M | 57.52M | |
| Cost of revenue | 1.46M |
Financial data from Vaxart earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 29 Jun 20 | Armistice Capital | Common Stock | Sell | Dispose S | No | 0 | 0 | 0 | 145,523 |
| 29 Jun 20 | Armistice Capital | Common Stock | Sell | Dispose S | No | 8.29 | 9,385,386 | 77.8M | 145,523 |
| 29 Jun 20 | Armistice Capital | Common Stock | Aquire X | No | 0 | 0 | 0 | 9,530,909 | |
| 29 Jun 20 | Armistice Capital | Common Stock | Aquire X | No | 1.1 | 4,090,909 | 4.5M | 9,530,909 | |
| 29 Jun 20 | Armistice Capital | Warrants Common Stock | Dispose X | No | 1.1 | 0 | 0 | 0 | |
| 29 Jun 20 | Armistice Capital | Warrants Common Stock | Dispose X | No | 1.1 | 4,090,909 | 4.5M | 0 | |
| 26 Jun 20 | Armistice Capital | Common Stock | Sell | Dispose S | No | 0 | 0 | 0 | 5,440,000 |
| 26 Jun 20 | Armistice Capital | Common Stock | Sell | Dispose S | No | 10.38 | 18,226,667 | 189.19M | 5,440,000 |
| 26 Jun 20 | Armistice Capital | Common Stock | Aquire X | No | 0 | 0 | 0 | 23,666,667 | |
| 26 Jun 20 | Armistice Capital | Common Stock | Aquire X | No | 0.3 | 16,666,667 | 5M | 23,666,667 |
Institutional ownership Q1 2020
41.0% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 38 |
| Opened positions | 19 |
| Closed positions | 2 |
| Increased positions | 8 |
| Reduced positions | 2 |
13F shares |
Current |
|---|---|
| Total value | 78.05M |
| Total shares | 30.39M |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|---|---|
| Armistice Capital | 25.2M | $44.6M |
| Renaissance Technologies | 2.17M | $3.85M |
| Vanguard | 644.54K | $1.14M |
| BLK BlackRock | 517.63K | $916K |
| Hussman Strategic Advisors | 500K | $885K |
| QS Investors | 377.75K | $669K |
| Geode Capital Management | 338.44K | $599K |
| Bank Julius Baer & Co. Ltd, Zurich | 242.76K | $432K |
| NTRS Northern Trust | 85.55K | $152K |
| Harvest Investment Services | 49.86K | $88K |
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
abetting, abnormally, affirming, aiding, al, anniversary, arena, assign, ATM, Attwill, bear, Carlo, CDMO, chosen, coating, complaint, complement, County, duty, economy, enrichment, equivalent, facilitate, fiduciary, Filer, GMP, Godfrey, headcount, inconvenient, intervening, intrinsic, KindredBio, lawsuit, LP, lyophilization, manipulated, marketplace, Mateo, Memorandum, Monte, nonrenewal, outsized, partnership, primate, purported, ramp, regional, reliant, resolution, revocation, Simulation, Speed, stable, Sterilflow, strictly, temperature, tranche, turn, unjust, unoccupied, unprecedented, upgrade, VAAST, Warp, waste
Removed:
allocate, calendar, capture, deployed, ensure, identifying, remain, reviewed, separately, specific, tied, understand, unforeseen
Financial reports
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
12 May 20
10-K
2019 FY
Annual report
19 Mar 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
6 Feb 19
10-Q
2018 Q3
Quarterly report
13 Nov 18
10-Q
2018 Q2
Quarterly report
10 Aug 18
10-Q
2018 Q1
Quarterly report
15 May 18
Current reports
8-K
Vaxart Announces Second Quarter 2020 Results
6 Aug 20
8-K
Other Events
13 Jul 20
8-K
Results of Operations and Financial Condition
8 Jul 20
8-K
Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP
30 Jun 20
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Jun 20
8-K
Regulation FD Disclosure
18 Jun 20
8-K
Vaxart, Inc. Appoints New CEO to Accelerate Advancement of COVID-19 and Other Programs
15 Jun 20
8-K
Departure of Directors or Certain Officers
9 Jun 20
8-K
Vaxart Announces First Quarter 2020 Financial Results
12 May 20
8-K
Vaxart Announces Corporate Update for First Quarter 2020
29 Apr 20
Registration and prospectus
S-3ASR
Automatic shelf registration
8 Jul 20
S-8
Registration of securities for employees
7 Jul 20
424B5
Prospectus supplement for primary offering
2 Mar 20
424B4
Prospectus supplement with pricing info
27 Sep 19
POS AM
Prospectus update (post-effective amendment)
27 Sep 19
FWP
Free writing prospectus
25 Sep 19
S-1/A
IPO registration (amended)
24 Sep 19
S-1/A
IPO registration (amended)
20 Sep 19
S-1
IPO registration
11 Sep 19
S-8
Registration of securities for employees
24 Apr 19
Proxies
DEFA14A
Additional proxy soliciting materials
15 May 20
DEFA14A
Additional proxy soliciting materials
24 Apr 20
DEF 14A
Definitive proxy
24 Apr 20
PRE 14A
Preliminary proxy
14 Apr 20
DEFA14A
Additional proxy soliciting materials
11 Mar 19
DEF 14A
Definitive proxy
11 Mar 19
PRE 14A
Preliminary proxy
28 Feb 19
DEF 14A
Definitive proxy
26 Feb 18
DEFA14A
Additional proxy soliciting materials
26 Feb 18
DFAN14A
Additional proxy materials by non-management
9 Feb 18
Other
EFFECT
Notice of effectiveness
3 Oct 19
EFFECT
Notice of effectiveness
27 Sep 19
CORRESP
Correspondence with SEC
26 Sep 19
CORRESP
Correspondence with SEC
26 Sep 19
CORRESP
Correspondence with SEC
23 Sep 19
CORRESP
Correspondence with SEC
23 Sep 19
UPLOAD
Letter from SEC
18 Sep 19
EFFECT
Notice of effectiveness
11 Apr 19
EFFECT
Notice of effectiveness
9 Apr 19
CORRESP
Correspondence with SEC
8 Apr 19
Ownership
4
Vaxart / Steven Boyd ownership change
30 Jun 20
SC 13D/A
Vaxart / ARMISTICE CAPITAL ownership change
30 Jun 20
4
Vaxart / Cezar Andrei Floroiu ownership change
17 Jun 20
4
Vaxart / Robert A. Yedid ownership change
9 Jun 20
4
Vaxart / Michael J. Finney ownership change
9 Jun 20
4
Vaxart / Todd C Davis ownership change
9 Jun 20
4
Vaxart / Cezar Andrei Floroiu ownership change
9 Jun 20
4
Vaxart / Margaret Echerd ownership change
9 Jun 20
4
Vaxart / Sean Tucker ownership change
9 Jun 20
4
Vaxart / Wouter Latour ownership change
9 Jun 20